×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
PR Newswire
Kazia CEO Dr. John Friend said: "We are pleased to announce we have exclusively licensed the development, manufacture and commercialization of...
1 month ago
Kazia concludes first stage of Phase I cancer treatment trial
Clinical Trials Arena
Kazia Therapeutics has announced the successful completion of the first stage of the Phase I trial of EVT801 in patients with advanced...
3 days ago
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED ...
FOX8 WGHP
SYDNEY, May 1, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology,...
4 days ago
Kazia Therapeutics' EVT801 Phase 1 clinical trial completes Phase 1 objectives - TipRanks.com
Tipranks
Kazia Therapeutics announced that the Safety Review Team of the EVT801 Phase 1 clinical trial has concluded that the primary and secondary objectives of...
3 days ago
Kazia Therapeutics hits milestone in EVT801 cancer trial
Investing.com
SYDNEY - Kazia Therapeutics Limited (NASDAQ: KZIA), an Australian biotechnology firm focused on cancer treatment development, announced the...
3 days ago
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
PR Newswire
The gross proceeds to the Company from the offering were approximately $2 million, before deducting the placement agent's fees and other...
5 months ago
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
PR Newswire
SYDNEY, Feb. 21, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specializing in oncology, today announced the early...
2 months ago
KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN ...
PR Newswire
Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2 study in...
6 months ago
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
PR Newswire
PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the...
3 months ago
KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY
PR Newswire
Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has...
6 months ago